John A Orwin
CIK 1477384 · PRESIDENT & CEO · last filed 2026-09-17
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
AFFY price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
700 SAGINAW DR.
REDWOOD CITY, CA 94063
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TRAX | Director | 17,995 | $45.45 | $817.9K | $0 | 5 | 2026-09-17 |
| ANAB | Director | 17,995 | $49.90 | $898.0K | $0 | 11 | 2026-09-17 |
| TVTX | Director | 39,375 | $50.07 | $1.97M | $0 | 6 | 2026-05-21 |
| CARGO Therapeutics, Inc. (CRGX) Delisted | Director | — | $4.47 | — | $0 | 4 | 2025-08-19 |
| Seagen Inc. (SGEN) Delisted | Director | 0 | $228.74 | $0 | $56.7K | 12 | 2023-12-15 |
| Atreca, Inc. (BCEL) Delisted | President & CEO | 100,492 | $0.15 | $15.1K | $39.6K | 8 | 2023-02-13 |
| Travere Therapeutics, Inc. (RTRX) Delisted | Director | 11,875 | — | — | $0 | 4 | 2020-05-19 |
| Relypsa Inc (RLYP) Delisted | President & CEO | 0 | — | — | -$3.61M | 12 | 2016-09-02 |
| AFFYMAX INC (AFFY) Delisted | CEO | 108,000 | — | — | -$4.78M | 18 | 2013-02-05 |
Recent Filings · Page 4 of 10
95 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-06-15 | Atreca, Inc. (BCEL) Delisted | Mixed | — | $0 | EDGAR |
| 2022-05-17 | Seagen Inc. (SGEN) Delisted | Grant (A) | +1,503 | $0 | EDGAR |
| 2022-05-12 | TVTX | Grant (A) | +3,000 | $0 | EDGAR |
| 2021-12-28 | Atreca, Inc. (BCEL) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-09-13 | Atreca, Inc. (BCEL) Delisted | Grant (A) | +115,400 | $0 | EDGAR |
| 2021-05-18 | TVTX | Grant (A) | +3,000 | $0 | EDGAR |
| 2021-05-18 | Seagen Inc. (SGEN) Delisted | Grant (A) | +1,402 | $0 | EDGAR |
| 2021-01-29 | Atreca, Inc. (BCEL) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-05-19 | Travere Therapeutics, Inc. (RTRX) Delisted | Grant (A) | +3,000 | $0 | EDGAR |
| 2020-05-19 | Seagen Inc. (SGEN) Delisted | Grant (A) | +1,335 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.